Medtronic Bolsters Board with Appointment of Dr. Joon Lee, Enhancing Healthcare Leadership

GALWAY, Ireland – June 23, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced a significant strategic move with the appointment of Dr. Joon Lee, the esteemed CEO of Emory Healthcare, Inc., to its Board of Directors. Dr. Lee joins as an independent director, with his tenure officially commencing on June 18, 2025. This addition is poised to bring invaluable expertise and a fresh perspective to Medtronic's governance and strategic direction.

Dr. Lee's appointment is particularly noteworthy given his extensive background in healthcare administration and his leadership role at Emory Healthcare, a prominent academic health system. His deep understanding of patient care, hospital operations, and the evolving healthcare landscape will be critical as Medtronic continues to innovate and expand its global reach in medical devices and therapies.

Strategic Committee Assignments

Upon joining the Board, Dr. Lee will serve on two pivotal committees: the Science and Technology Committee and the Compensation and Talent Committee. His role on the Science and Technology Committee underscores Medtronic's commitment to fostering innovation and leveraging cutting-edge technologies to address complex health challenges. Dr. Lee's experience in a leading healthcare institution will provide practical insights into the adoption and impact of new medical technologies, ensuring Medtronic's R&D efforts remain aligned with clinical needs and market demands.

Furthermore, his inclusion in the Compensation and Talent Committee highlights Medtronic's focus on attracting, retaining, and developing top-tier talent. In an increasingly competitive healthcare technology sector, strong leadership and a robust talent pipeline are essential for sustained growth and market leadership. Dr. Lee's executive experience will be instrumental in shaping compensation strategies that incentivize performance and foster a culture of excellence.

Market Context and Implications for Medtronic

This board appointment comes at a dynamic time for the healthcare technology industry. Companies like Medtronic are navigating rapid technological advancements, evolving regulatory environments, and increasing demands for value-based care. The addition of a seasoned healthcare executive like Dr. Lee can significantly strengthen Medtronic's ability to adapt to these changes and capitalize on emerging opportunities.

From a market perspective, this move signals Medtronic's dedication to enhancing its strategic oversight and operational efficiency. Investors often view strong corporate governance and the inclusion of highly qualified independent directors as positive indicators of a company's long-term stability and growth potential. Dr. Lee's appointment could reinforce investor confidence in Medtronic's leadership and its capacity to execute its strategic objectives effectively.

Investment Insights

For investors, the appointment of Dr. Joon Lee to Medtronic's Board of Directors is a positive development. It suggests a proactive approach by Medtronic to strengthen its leadership team with diverse and relevant expertise. Key takeaways for investors include:

• Enhanced Strategic Direction: Dr. Lee's deep healthcare operational experience can provide valuable insights into market trends, patient needs, and clinical integration, potentially leading to more effective product development and market penetration strategies.
• Improved Governance: The addition of an independent director with a strong track record in a major healthcare system can bolster corporate governance, which is often a key factor for institutional investors.
• Focus on Innovation and Talent: His roles on the Science and Technology and Compensation and Talent Committees indicate Medtronic's continued emphasis on R&D and human capital, both critical drivers of long-term value in the healthcare technology sector.

While a single board appointment typically doesn't trigger significant stock price movements, it contributes to the overall narrative of a well-managed and forward-thinking company. Investors should view this as a reinforcing factor for Medtronic's long-term investment thesis, particularly for those focused on stability and strategic growth in the medical device industry. This move aligns with Medtronic's ongoing efforts to maintain its leadership position and drive innovation in healthcare technology.

Conclusion

Medtronic's appointment of Dr. Joon Lee is a strategic enhancement to its Board of Directors, bringing a wealth of healthcare leadership and operational expertise. This move is expected to strengthen the company's strategic planning, foster innovation, and reinforce its commitment to robust corporate governance, ultimately benefiting its stakeholders and solidifying its position as a leader in global healthcare technology.